at Benzinga.com (Dec 30, 2014)
Dendreon (DNDN +1.1%) sells its immunotherapy manufacturing facility in Morris Plains, New Jersey, to Novartis (NVS) for $43M in cash. The sale is part of Dendreon's restructuring plans on "its path to profitability and future growth." The plant was used to manufacture cancer drug Provenge, which has had its marketing troubles.
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Nov 18, 2014)
at Zacks.com (Nov 11, 2014)
at CNBC.com (Nov 10, 2014)
at Zacks.com (Nov 10, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs